Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

NCT01790503 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT01790503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01790503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Lead sponsor
Daiichi Sankyo
Phase
Phase 1/2
Overall status
Completed
Start date
July 18, 2013
Completion date
March 4, 2020
Enrollment
65 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

patients with newly diagnosed glioblastoma